

PRESS RELEASE

GEOVAX, INC. COMPLETES MERGER WITH DAUPHIN TECHNOLOGY, INC.

Combined New Entity Named GeoVax Labs, Inc.

FOR IMMEDIATE RELEASE

ATLANTA, GA & SCHAUMBURG, IL, USA October 3, 2006 -- GeoVax, Inc., a privately held biotechnology company based in Atlanta, Georgia, today announced that on September 28, 2006 it completed its merger with Dauphin Technology, Inc. ("Dauphin"), a publicly traded company based in Schaumburg, Illinois.

Upon closing the merger, Dauphin's name was changed to GeoVax Labs, Inc. ("GeoVax") and it was assigned a new CUSIP number: 373678101. GeoVax' common stock is now quoted on the NASDAQ OTCBB under the symbol DNTK.OB, and for a period of time will continue trading on the Pink Sheets under the symbol DNTK.PK. GeoVax will announce its new stock symbol on its website at www.geovax.com as soon as it is available.

Mr. Don G Hildebrand, GeoVax Inc President and Chairman of the Board of Directors, stated, "on behalf of our team and Board of Directors, I want to thank all our shareholders and the shareholders of Dauphin for their loyalty and support of our merger with Dauphin. We look forward to enhancing our AIDS vaccine development program with the additional financial resources the merger will provide."

GeoVax initiated a planned series of four human clinical trials in April 06 with its DNA and MVA AIDS vaccines at several sites in the USA. The second trial of this series began the last week of Sept 06. A previous human clinical trial with its DNA vaccine was satisfactorily completed.

Safe Harbor Statement

All statements in this news release that are not statements of historical fact are forward-looking statements. These statements are based on expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties which could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, whether; GeoVax can develop vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be determined to be safe for use in humans, GeoVax's vaccines will be effective in preventing AIDS in humans, the vaccines will receive the regulatory approvals necessary to be licensed and marketed, GeoVax can raise the required capital to complete development of its vaccines, there is development of competitive products that may be more effective or easier to use than GeoVax's products, and other factors over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements. Further risks are detailed in the Company's Securities and Exchange Commission filings and reports..
